Highlights Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 08:38:07 2024-06-14 am EDT			5-day change	1st Jan Change
95.02 ^CHF	+0.80%		-0.15%	+11.71%

11:31am	PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	MT
Jun. 11	NOVARTIS AG : JP Morgan reiterates its Neutral rating	ZD

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	05:31am	MT
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	Jun. 07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	Jun. 07	MT
Novartis and others face Italy antitrust probe over eye drug	Jun. 06	RE
Three newcomers to the MDax - Rational, TUI and Traton move up	Jun. 06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	Jun. 05	DJ
NOVARTIS : UBS reiterates buy recommendation after ASCO	Jun. 03	CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	Jun. 02	RE
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	May. 31	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	May. 31	MT
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	May. 31	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	May. 31	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	May. 31	MT
Novartis: positive trial results in chronic myeloid leukemia	May. 31	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	May. 31	MT
Novartis Presents Positive Results from the Pivotal Phase III ASC4FIRST Trial	May. 31	CI
Novartis: efficacy of remibrutinib in urticaria -USC	May. 31	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	May. 30	MT
Novartis Phase III Data Confirms Sustained Efficacy and Long-Term Safety of Oral Remibrutinib in Chronic Spontaneous Urticaria	May. 30	CI
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	May. 30	DJ